08:00 , Nov 14, 2013 |  BC Innovations  |  Targets & Mechanisms

RSVing for site zero

Despite decades of research, respiratory syncytial virus (RSV) remains a highly prevalent childhood pathogen without an approved vaccine. 1 There is a marketed prophylactic- Synagis palivizumab-to prevent severe disease caused by RSV in at-risk infants,...
07:00 , Mar 15, 2010 |  BioCentury  |  Strategy

Where to fit in at AstraZeneca

AstraZeneca plc 's decision to stop discovery efforts in previously key indications does not mean the company is no longer interested in developing drugs in those areas - it just intends to focus its internal...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Company News

AstraZeneca pharmaceuticals news

AstraZeneca released further details of plans to reorganize its R&D, including its intention to end discovery efforts in 10 indications. AstraZeneca plans to cease work in thrombosis, acid reflux, ovarian and bladder cancers, systemic scleroderma,...
01:51 , Mar 3, 2010 |  BC Extra  |  Company News

AstraZeneca details restructuring plans

AstraZeneca plc (LSE:AZN; NYSE:AZN) released further details of plans to reorganize its R&D, including its intention to end discovery efforts in 10 indications. AstraZeneca plans to cease work in thrombosis, acid reflux, ovarian and bladder...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

Immune Targeting Systems board of directors update

Immune Targeting Systems Ltd. , London, U.K.   Business: Infectious   Appointed: Ken Powell, formerly CEO of Arrow Therapeutics Ltd. (now part of AstraZeneca plc ), as non-executive chairman  ...
07:00 , Jun 22, 2009 |  BioCentury  |  Emerging Company Profile

Beactica: More Efficient Resonance

Surface plasmon resonance, or SPR, is used in fragment-based drug discovery because it provides a wealth of information about how a compound or fragment interacts with its target. Beactica AB is seeking to improve the...
08:00 , Jan 19, 2009 |  BC Week In Review  |  Company News

AstraZeneca management update

AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.   Business: Pharmaceuticals   Departing: Ken Powell as head of AstraZeneca's Arrow Therapeutics Ltd. subsidiary; Research Director Stuart Cockerill will become interim head  ...
07:00 , May 26, 2008 |  BioCentury  |  Finance

Midlife crisis

Investor enthusiasm for European biotech is falling away just as the industry's capital demand continues to rise in response to a plethora of maturing clinical programs. Investors are shying away from mid-stage companies, preferring either...
07:00 , Apr 17, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV HIV glycoprotein envelope; nonstructural protein 5A (NS5A); C5A A study in cell culture suggests that an HCV-derived peptide could...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Company News

Beactica, AstraZeneca deal

Beactica will use its fragment-based technology to characterize compounds from AZN's Arrow Therapeutics Ltd. subsidiary against an undisclosed antiviral target. Arrow will own resulting IP. Further terms were not disclosed. Beactica AB , Uppsala, Sweden...